Genome & Company·LabGenomics Rally in K...

This article was released as Pharm Edaily Premium Content on June 10, 2026, at 8:00 AM.[Seungkwon Kim, Edaily Reporter] South Korean pharmaceutical, biotech and healthcare stocks staged a broad-based rally on June 9, as sector-specific catalysts drove sharp gains in select names amid an otherwise macro-driven market. While benchmark indices were buoyed by strength in semiconductors and secondary batteries, it was company-specific newsflow spanning imminent drug licensing deals, institutional capital inflows and next-generation AI hardware wins that propelled GenomeAndCompany, LabGenomics and KohYoung to outsized moves. Genome & Company drew the heaviest attention after signaling an accelerated timeline for antibody-drug conjugate (ADC) out-licensing.Genome & Company, ADC Pipeline Repricing UnderwayGenome & Company closed up approximately 25% at KRW 6,080, its sharpest single-session gain in recent memory. The catalyst was an investor briefing held at Conrad Seoul in Yeouido, where management laid out an aggressive licensing roadmap: at minimum one deal each in 2025 and 2026, anchored by two novel-target ADC assets.The company, originally built on microbiome-based drug discovery, formally pivoted its R&D strategy in 2023 toward proprietary-target ADCs a shift management described as a response to the increasingly winner-take-all dynamics of the global oncology market. The two lead assets are GENA-104, targeting the novel immune checkpoint CNTN4 (Contactin-4), and GENA-120, directed against integrin β4 (ITGB4).GENA-104, which received its first full preclinical profile disclosure at the American Association for Cancer Research (AACR) annual meeting this year, is distinguished by a dual mechanism of action: in addition to conventional payload-mediated cytotoxicity, the compound restores T-cell-mediated tumor killing suppressed by CNTN4 overexpression on cancer cells. In patient-derived xenograft (PDX) models, GENA-104 achieved a tumor growth inhibition (TGI) rate exceeding 100% in tumors with H-scores above 150. High CNTN4 expression was confirmed across melanoma including acral and mucosal subtypes with historically poor immunotherapy response rates as well as hepatocellular carcinoma, non-small cell lung cancer and sarcoma.GENA-120, disclosed publicly for the first time at Monday's briefing, targets ITGB4, an antigen with confirmed tumor-specific overexpression across colorectal, head and neck, esophageal, gastric, cervical and lung cancers. In vitro data demonstrated potent ITGB4 expression-dependent cytotoxicity and induction of immunogenic cell death. The company's closest known competitor in this space is China's SystImmune, which presented a poster on the same target at AACR 2025 and has flagged a China IND filing in Q4 2025."The commercial landscape for validated-target ADCs is already locked up by first movers," said CEO Hong Yu-seok. "Our thesis is that first-in-class entry even with an average efficacy profile retains commercial viability, whereas best-in-class latecomers in crowded targets struggle to gain traction. Current market capitalization does not adequately reflect the potential of our novel ADC assets."A sell-side analyst covering Korean biotech noted: "Genome & Company's proactive positioning in underpenetrated target classes is a meaningful differentiator. In an environment where global biopharma is aggressively scouting ADC pipeline additions, the probability of a meaningful preclinical licensing deal has materially increased. A confirmed out-licensing transaction would serve as a significant re-rating catalyst."The company also highlighted its dual-antibody ADC GNB-120, which co-targets ITGB4 and HER2 using a 1+1 avidity structure designed to restrict binding to cells co-expressing both antigens — a strategy aimed at tackling HER2-positive indications currently inaccessible to approved HER2 ADCs. In pancreatic cancer cell lines, GNB-120 demonstrated up to a 7-fold improvement in anti-tumor efficacy versus